Search Results - "Halton, Elizabeth F."

Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy by Wudhikarn, Kitsada, Flynn, Jessica R., Rivière, Isabelle, Gönen, Mithat, Wang, Xiuyan, Senechal, Brigitte, Curran, Kevin J., Roshal, Mikhail, Maslak, Peter G., Geyer, Mark B., Halton, Elizabeth F., Diamonte, Claudia, Davila, Marco L., Sadelain, Michel, Brentjens, Renier J., Park, Jae H.

“…CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has become a breakthrough treatment of patients with relapsed/refractory B-cell acute…”
Get full text

Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management by Pennisi, Martina, Jain, Tania, Santomasso, Bianca D., Mead, Elena, Wudhikarn, Kitsada, Silverberg, Mari Lynne, Batlevi, Yakup, Shouval, Roni, Devlin, Sean M., Batlevi, Connie, Brentjens, Renier J., Dahi, Parastoo B., Diamonte, Claudia, Giralt, Sergio, Halton, Elizabeth F., Maloy, Molly, Palomba, Maria Lia, Sanchez-Escamilla, Miriam, Sauter, Craig S., Scordo, Michael, Shah, Gunjan, Park, Jae H., Perales, Miguel-Angel

“…Various grading systems are currently used for chimeric antigen receptor (CAR) T-cell–related toxicity, cytokine release syndrome (CRS), and immune effector…”
Get full text

Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells by Pennisi, Martina, Sanchez-Escamilla, Miriam, Flynn, Jessica R., Shouval, Roni, Alarcon Tomas, Ana, Silverberg, Mari Lynn, Batlevi, Connie, Brentjens, Renier J., Dahi, Parastoo B., Devlin, Sean M., Diamonte, Claudia, Giralt, Sergio, Halton, Elizabeth F., Jain, Tania, Maloy, Molly, Mead, Elena, Palomba, Maria Lia, Ruiz, Josel, Santomasso, Bianca, Sauter, Craig S., Scordo, Michael, Shah, Gunjan L., Park, Jae H., Yanez San Segundo, Lucrecia, Perales, Miguel-Angel

“…Patients who develop chimeric antigen receptor (CAR) T-cell–related severe cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity…”
Get full text

Abstract CT036: A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy by Adusumilli, Prasad S., Zauderer, Marjorie G., Rusch, Valerie W., O'Cearbhaill, Roisin E., Zhu, Amy, Ngai, Daniel A., McGee, Erin, Chintala, Navin K., Messinger, John C., Vincent, Alain, Halton, Elizabeth F., Diamonte, Claudia, Pineda, John, Modi, Shanu, Solomon, Stephen B., Jones, David R., Brentjens, Renier J., Rivière, Isabelle, Sadelain, Michel

“…Abstract Background: Malignant pleural disease (MPD) from primary malignant pleural mesothelioma (MPM) or secondary metastatic disease (lung and breast…”
Get full text